Home Company

About

Genalyte is a health care diagnostics and analytics company that improves patient outcomes and lowers cost by offering real-time laboratory results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing.

Home Company

Leadership

Our leadership team draws on diverse backgrounds spanning healthcare and technology.

ASHRAF HANNA, MD PHD

ASHRAF HANNA, MD PHD

CEO

Ashraf Hanna is the Chief Executive Officer at Genalyte. 

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer.  Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic.  Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers.   Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials.  ORIC had an IPO at approximately $1B valuation while still in Phase 1.   Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance.  He started his work career at McKinsey and Company.  Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.  

HOSSEIN FAKHRAI-RAD, PHD

HOSSEIN FAKHRAI-RAD, PHD

CSO

Hossein is an experienced entrepreneur who has worked on developing various technologies and models for identification and characterization of numerous risk factors for common complex diseases for the past 20 years.

Hossein founded BaseHealth in 2011, a predictive health analytics company that empowered leading health systems and Medicare Advantage plans to maximize revenues, cost-savings and clinical outcomes through a proprietary machine learning and artificial intelligence platform built on the most diverse and comprehensive set of data types in the industry. Prior to BaseHealth, Hossein was a founding member of ParAllele Bioscience, a startup company
that developed two main technologies for identification and scanning of genetic variations. ParAllele was acquired by Affymetrix where Hossein led the development and management of Affymetrix’s Genetic service lab.
Hossein earned his PhD in Medical Genetics from the Karolinska Institute in Sweden and completed his
post-Doctoral fellowship at the Stanford Genome Technology Center. He has written over 20 peer-reviewed
publications in Journals and books and holds a number of pending and issued patents.

RICK HOCKETT, MD

RICK HOCKETT, MD

CMO

A clinical pathologist certified by the American Board of Pathology, Chief Medical Officer Rick Hockett is the mind behind Genalyte’s clinical strategy, development and operations.

Dr. Hockett oversees the daily operations of Genalyte’s CLIA laboratory and 510(k) submission of Genalyte’s proprietary diagnostic instrumentation and assays for regulatory approval. Dr. Hockett has spent three decades applying biomarkers to clinical medicine, distinguishing himself as a leader in personalized medicine. Among many professional achievements, Dr. Hockett was responsible for the first standalone genetic component for a New Drug Application to the U.S. Food and Drug Administration. He maintains active medical licenses in Indiana, California, New York and Colorado. Dr. Hockett earned his bachelor’s degree in Chemistry at the University of South Dakota and his Doctorate of Medicine from the University of Minnesota; he completed his residency in Clinical Pathology at Washington University, St. Louis.

PRAKASH MENON

PRAKASH MENON

CTO

Prakash has always been intrigued by the promise of data-based medical care and, in particular, it’s role in moving to a more prevention-based paradigm.

In addition to a very strong foundation in enterprise software development, Prakash has executive experience leading organizations through multiple stages of growth in uncertain markets. As CTO of BaseHealth, Prakash built and delivered five novel products and architected a cloud-based platform that ran ML pipelines that processed 350 million data points over  263,000 lives across hybrid cloud technologies. Prior to that Prakash led the software development and analytics function at Hara Software, a KPCB backed startup that defined and led the market in Enterprise Energy Management. Prior to Hara Software, Prakash spent more than a decade at Oracle, working with and leading teams that built cutting edge performance management solutions for distributed Enterprise applications.  Prakash holds a bachelor’s degree in Engineering from National Institute of Technology, Calicut, and a master’s degree in Business from T.A.Pai Management Institute, Manipal.

MICHAEL O’NEIL

MICHAEL O’NEIL

VP, Product Marketing

Michael leads Genalyte’s strategic direction by reading the market, identifying key market segments and designing innovative products and services to meet those needs.  As part of a twenty year career at Blue Shield of California, Michael spearheaded the design and implementation of one of the first Accountable Care Organizations (ACOs) in the country while serving as Senior Director of Product Innovation. Improving quality of healthcare while cutting costs by almost $38 million in two years for 40K CalPERS members, the ACO model has been replicated by more than 32 medical groups and hospitals across the state.  Michael later became Vice President of Product and Market Alignment at Blue Shield of California where he oversaw product innovation and management for all Commercial offerings including the adoption of and transition to the Affordable Care Act.  Michael earned his bachelor’s degree in Political Science from Dartmouth College and a master’s degree in Education from Stanford University.

SASI MUDUMBA, PHD

SASI MUDUMBA, PHD

VP, Assay Development

Dr. Mudumba oversees the research, development, validation, regulatory submission and approval of the diagnostic assays at the heart of Genalyte’s revolutionary technology.

Dr. Mudumba has spent more than 20 years in research, development and commercialization in the life sciences, pharmaceutical and medical device industries. Dr. Mudumba has guided several In Vitro Diagnostics (IVD) products through approvals at federal agencies including the Food and Drug Administration and Health Canada, and was responsible for leading a multiplexed autoimmune IVD assay on microarray technology from development to regulatory approval. Her previous roles include Director of Assay Development of Regulatory Affairs at SQI Diagnostics and Senior Scientist at NoAb BioDiscoveries. Dr. Mudumba earned her bachelor’s degree in Microbiology at Osmania University before obtaining her master’s degree in Biochemistry from the University of Hyderabad; her PhD in Biotechnology is from Jawaharlal Nehru Technological University.

MADONNA MORENO

MADONNA MORENO

Director, Human Resources

A 19-year veteran of her field, Madonna Moreno can be credited with shaping Genalyte’s innovative, dynamic culture by dictating company values and people strategy.

Madonna is responsible for Genalyte’s Human Resources function including talent management, employee development, benefits, compensation, and business support.  A leader in her field, Madonna is President of the San Diego Life Sciences HR Network, a nonprofit organization dedicated to developing innovation and strategic human resource practices in the life sciences industry. Madonna is a Certified Professional in Human Resources and a Society for Human Resources Certified Professional.  Having spent 11 years in biotechnology and life sciences companies — including Trovagene and the Salk Institute for Biological Studies — Madonna is passionate about working with innovative thinkers, and connecting talented people with meaningful opportunities to impact health and change lives.  Madonna holds a bachelor’s degree in Political Science and a master’s in Business Administration, both from the University of San Diego. 

Board of Directors

ASHRAF HANNA

CEO

Ashraf Hanna is the Chief Executive Officer of Genalyte. 

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer.  Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic.  Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers.   Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials.  ORIC had an IPO at approximately $1B valuation while still in Phase 1.   Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance.  He started his work career at McKinsey and Company.  Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.  

CARY GUNN

Member, Board of Directors

Dr. Cary Gunn has been blazing trails in the technology community for almost 30 years.

Prior to founding Genalyte, Cary served as co-founder and Chief Technical Officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in Applied Physics and Organic Chemistry from the United States Air Force Academy and his PhD in Electrical Engineering from the California Institute of Technology (Caltech).

SAEID AKHTARI

Member, Board of Directors

Saeid is the Managing Director at HBM Genomics investing in world-class entrepreneurs in life sciences companies.

He has more than 25 years of experience as an entrepreneur building successful biotech companies from scratch. Saeid is an active investor/advisor in leading life sciences companies, including Genalyte, Clear Labs, Convergent Genomics, Encoded Therapeutics, Haystack Biosciences, Seer Biosciences, Trace Genomics, and Xcell Biosciences.

Prior to HBM Genomics, Saeid was the founder, President & CEO of NextBio which was acquired by Illumina in 2013. Prior to founding NextBio, he was the President & CEO of Silicon Genetics which was acquired by Agilent in 2004. Mr. Akhtari has also held executive management positions at several other life sciences companies.

ANDREW CONRAD

Member, Board of Directors

Andrew Conrad, PhD, is the Chief Executive Officer, Chairman and Founder of Verily where he oversees an integrated team of engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects.
Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

JEFF HUBER

Member, Board of Directors

Jeff Huber is the Founding CEO and Vice Chairman of GRAIL (2016-present). GRAIL’s mission is to detect cancer early, when it can be cured.

Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google’s life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology, including Openwater, Mammoth Biosciences, Vir, Sana, Zymergen, Atomwise, Genalyte, Pinterest, Honor, OpenDoor, and AngelList.

Jeff holds a bachelor’s degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a ‘Distinguished Alumni Award’ from the College of Electrical & Computer Engineering (2018) for ‘challenging the status quo through innovation’. He also holds a master’s degree in business from Harvard University. Jeff is a board member of GRAIL (Vice Chairman), Genalyte (Chairman), Electronic Arts (EA), Openwater, and The Exploratorium, and a former board member of Illumina (ILMN; 2014-2016).

JOE MARKEE

Member, Board of Directors

Joe Markee Managing Director at Express Ventures

Joe brings extensive experience in early stage company formation, capital raising, corporate management, and public and private corporate governance. Joe’s startup experience encompasses Primary Access as a founder and senior manager, Copper Mountain Networks as founding CEO, CTO and Chairman, Figure 8 Wireless as CEO and StackIQ as CEO and Chairman.

Joe was also a founder and served as President of the San Diego Telecommunications Council (renamed CommNexus). He has been honored with awards for his contributions to San Diego’s high-tech business community, including Master Entrepreneur.

GERARD VAN HAMEL PLATERINK

Member, Board of Directors

Gerard joined Redmile as a managing director in May 2012.

Prior to working with Redmile, Gerard was a Managing Director with Accuitive Medical Ventures (AMV). AMV II has recently been ranked in the top quartile of healthcare VC funds for its vintage year (Source: Cambridge Assoc.). Gerard has cofounded a number of healthcare companies including Halscion, Sebacia and First Aid Shot Therapeutics. In addition, Gerard led AMV’s investments in Axogen (public: AXGN), Cardiofocus, Neuronetics and Intuity Medical. Before AMV, Gerard worked with Novoste Corporation, the cardiology technology company, in business development and corporate communications. Before joining Novoste, Gerard was an equity research analyst with Salomon Brothers (now Citigroup) in London, where he was a member of the top ranked European healthcare research team. Gerard began his career with Kleinwort Benson, where he was an investment banker and member of the bank’s private equity and mezzanine finance group. Gerard is a Dutch national, was born in Borneo in Southeast Asia, grew up in Africa and was educated in the UK where he got his BS in Physics (1st Class Honors) from St. Andrews University and an MBA from Cambridge University.

RAJESH SWAMINATHAN

Member, Board of Directors

Rajesh is a Partner at Khosla Ventures. Rajesh brings with him two decades of experience assisting and investing in deeptech/ hardware startups across many industries including Cleantech and Healthcare.
Before joining Khosla Ventures, Rajesh served as the Head of Applied Ventures LLC, the Venture Capital arm of Applied Materials, where he managed a portfolio of over 85 hardware startups across 13 countries. Rajesh also drove the establishment of an $850M Materials Engineering Technology Accelerator (META) facility in NY, to enable access of semiconductor fabs for startups. Rajesh received Global Corporate Venturing’s (GCV) Powerlist award in 2019.

Before joining Applied Ventures, Rajesh worked at the venture arm of Third Point LLC. Previously, at Lucent’s Bell Labs, he drove the technical assessment & partnerships with several Photonics, MEMS and RF startups. Rajesh also led the design for reliability program for Lucent’s 10Gb/s and 40Gb/s telecommunication systems and supported the successful deployment of these systems globally.

While pursuing his MBA at Harvard Business School, Rajesh interned at Deutsche Bank’s cleantech investment banking group. Rajesh completed his M.S. at the University of Maryland at College Park, and received his Bachelor’s degree in Chemical Engineering from IIT Madras where he was awarded the Shankar Dayal Sharma (President of India) Medal for overall excellence.

Investors